JP2023506691A5 - - Google Patents
Info
- Publication number
- JP2023506691A5 JP2023506691A5 JP2022528124A JP2022528124A JP2023506691A5 JP 2023506691 A5 JP2023506691 A5 JP 2023506691A5 JP 2022528124 A JP2022528124 A JP 2022528124A JP 2022528124 A JP2022528124 A JP 2022528124A JP 2023506691 A5 JP2023506691 A5 JP 2023506691A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911109773.2 | 2019-11-13 | ||
| CN201911109773 | 2019-11-13 | ||
| CN201911288492 | 2019-12-13 | ||
| CN201911288492.8 | 2019-12-13 | ||
| CN202010096582 | 2020-02-17 | ||
| CN202010096582.3 | 2020-02-17 | ||
| CN202010711270.9 | 2020-07-22 | ||
| CN202010711270 | 2020-07-22 | ||
| PCT/CN2020/128597 WO2021093839A1 (zh) | 2019-11-13 | 2020-11-13 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506691A JP2023506691A (ja) | 2023-02-20 |
| JP2023506691A5 true JP2023506691A5 (https=) | 2023-02-28 |
| JP7473642B2 JP7473642B2 (ja) | 2024-04-23 |
Family
ID=75912541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528124A Active JP7473642B2 (ja) | 2019-11-13 | 2020-11-13 | Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12378253B2 (https=) |
| EP (1) | EP4059935A4 (https=) |
| JP (1) | JP7473642B2 (https=) |
| KR (1) | KR102793446B1 (https=) |
| CN (2) | CN117551103A (https=) |
| WO (1) | WO2021093839A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4234558A4 (en) * | 2020-12-07 | 2024-10-23 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF |
| WO2022213932A1 (zh) * | 2021-04-06 | 2022-10-13 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
| CN114761410B (zh) * | 2021-04-06 | 2023-08-25 | 广州必贝特医药股份有限公司 | 吡咯并嘧啶酮类化合物及其应用 |
| EP4339198A4 (en) * | 2021-05-12 | 2025-06-11 | Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. | CRYSTAL FORM OF A PYRROLOPYRIMIDINE COMPOUND AND METHOD FOR PREPARING THE CRYSTAL FORM |
| KR20240157639A (ko) | 2021-12-14 | 2024-11-01 | 크로스파이어 온콜로지 홀딩 비.브이. | 거대고리 btk 억제제 |
| CN115894500B (zh) * | 2022-11-02 | 2024-05-28 | 中国药科大学 | 一种作为btk激酶抑制剂的化合物及其制备方法与用途 |
| CN118702697A (zh) * | 2023-03-18 | 2024-09-27 | 山东新时代药业有限公司 | 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法 |
| CN116375715B (zh) * | 2023-04-06 | 2025-04-04 | 中国药科大学 | 一种作为非共价btk激酶抑制剂的化合物及其生物用途 |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024246287A1 (en) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Medical use of a macrocyclic reversible btk inhibitor |
| WO2024256568A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Salt and crystal forms of a macrocyclic btk inhibitor |
| WO2024256574A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Process for preparing macrocyclic btk inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI398252B (zh) * | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| EP3170825B1 (en) * | 2012-08-06 | 2019-04-10 | ACEA Biosciences Inc. | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
| EP3042903B1 (en) * | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| SI3882250T1 (sl) * | 2015-12-23 | 2023-07-31 | Arqule, Inc. | Tetrahidropiranil amino-pirolopirimidinon za uporabo pri zdravljenju z BTK posredovanih motenj |
| TW201811795A (zh) * | 2016-08-24 | 2018-04-01 | 美商亞闊股份有限公司 | 胺基－吡咯并嘧啶酮化合物及其用途 |
-
2020
- 2020-11-13 JP JP2022528124A patent/JP7473642B2/ja active Active
- 2020-11-13 CN CN202311079865.7A patent/CN117551103A/zh not_active Withdrawn
- 2020-11-13 CN CN202080078768.4A patent/CN114728974B/zh active Active
- 2020-11-13 KR KR1020227018702A patent/KR102793446B1/ko active Active
- 2020-11-13 US US17/776,873 patent/US12378253B2/en active Active
- 2020-11-13 WO PCT/CN2020/128597 patent/WO2021093839A1/zh not_active Ceased
- 2020-11-13 EP EP20887944.5A patent/EP4059935A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023506691A5 (https=) | ||
| US20250243204A1 (en) | Fgfr inhibitors and methods of making and using the same | |
| WO2025067459A2 (en) | Therapies for the treatment of cancer | |
| CN114516857A (zh) | Hpk1抑制剂及其用途 | |
| EP3176160A1 (en) | Pyridine-substituted 2-aminopyridine protein kinase inhibitors | |
| JP7830540B2 (ja) | ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス | |
| US20100087458A1 (en) | Method of treating melanoma | |
| JPH05163148A (ja) | 抗腫瘍剤 | |
| CN117083265A (zh) | 激酶抑制剂及其用途 | |
| CN119745884A (zh) | 一种用于治疗非小细胞肺癌的丙酮酸盐制剂及其制备方法 | |
| JP7664429B2 (ja) | Ｆｇｆｒ４選択的阻害剤の塩及びその製造方法と用途 | |
| KR20220124739A (ko) | 암의 치료를 위한 병용 요법 | |
| JP2007510751A (ja) | 新規化合物、対応する組成物、調製方法および／または治療方法 | |
| CN120774918A (zh) | 蛋白降解剂类化合物及其制备方法、药物组合物和应用 | |
| JP7509340B2 (ja) | トリゴネリンベースの化合物 | |
| CN118525012A (zh) | 奥希替尼共晶及制备方法以及作为药物或在药物制剂中的应用 | |
| CN115260107B (zh) | 一种抗肿瘤药物前药、药物组合物及在肿瘤靶向治疗领域的应用 | |
| CN118994161B (zh) | 一种(s)-2-(4-(4-甲基-1-哌嗪基)苯胺基)-8-苯胺基-9-(3-哌啶基)-9h-嘌呤及其应用 | |
| CN106146612B (zh) | 一类乙二醛酶i不可逆抑制剂及其制备方法和用途 | |
| EP3956287B1 (en) | Prodrugs of monomethyl fumarate | |
| JPH0132826B2 (https=) | ||
| CN113527331B (zh) | 硝基咪唑类衍生物及其制备方法和用途 | |
| TWI324516B (en) | Fused tri-heterocyclic compounds | |
| WO2026061536A1 (zh) | Yap/taz与tead相互作用抑制剂与紫杉烷类药物的联用用途 | |
| CN121991143A (zh) | 一种2-乙酰氨基葡萄糖硫酸钾盐及其制备方法与应用 |